United States securities and exchange commission logo
June 9, 2023
Patrick McCloskey
Managing Member
McCloskey Law PLLC
425 Madison Avenue, Suite 1700
New York, NY 10017
Re: Enochian
Biosciences Inc.
Schedule 13D filed
by Weird Science LLC and William Anderson Wittekind
Filed May 19, 2023
File No. 005-86428
Dear Patrick McCloskey:
We have reviewed the
above-captioned filing, and have the following comments.
Please respond to this letter by amending the filing or by
providing the requested
information. If a belief exists that our comments do not apply to your
facts and circumstances or
that an amendment is inappropriate, please advise us why in a response
letter.
After reviewing any amendment to the filing and any information
provided in response
to these comments, we may have additional comments.
Schedule 13D filed May 19, 2023
General
1. We note the date of the
event reported as requiring the filing of the Schedule 13D was
February 16, 2018. Rule
13d-1(a) of Regulation 13D-G requires the filing of a Schedule
13D within 10 days
after the acquisition of more than five percent of a class of equity
securities specified in
Rule 13d-1(i). Based on the February 16, 2018 event date, the
Schedule 13D submitted
on May 19, 2023 was not timely filed. Please advise us why the
Schedule 13D was not
filed within the required 10 days after the acquisition.
2. Please amend the
Schedule 13D to include disclosure responsive to Item 5(c) of Schedule
13D, which requires
beneficial owners reporting on Schedule 13D to provide a description
of "any transactions in
the class of securities reported on that were effected during the past
sixty days...." To the
extent transactions have occurred within that time period,
the description must
include, at a minimum, the following: (1) The identity of the person
covered by Item 5(c)
who effected the transaction; (2) the date of transaction; (3) the
amount of securities
involved; (4) the price per share or unit; and (5) where and how the
Patrick McCloskey
McCloskey Law PLLC
June 9, 2023
Page 2
transaction was effected. To the extent that no such reportable
transactions
occurred, please affirmatively so state. See Instruction A within the
Special Instructions
for Complying With Schedule 13D at Rule 13d-101 of Regulation 13D-G.
We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please direct any questions to Michael Killoy at (202) 551-7576 or
Nicholas Panos at
(202) 551-3266.
FirstName LastNamePatrick McCloskey Sincerely,
Comapany NameMcCloskey Law PLLC
Division of
Corporation Finance
June 9, 2023 Page 2 Office of
Mergers & Acquisitions
FirstName LastName